Key result
MALAT1 knockdown significantly ameliorated diabetic retinopathy in vivo by reducing pericyte loss and microvascular leakage, and regulated endothelial cell function via p38 MAPK signaling.
Why the study?
Does MALAT1 knockdown improve retinal microvascular dysfunction in diabetic models?
Population
STZ-induced diabetic rats, db/db mice, and RF/6A retinal endothelial cells
Comparison
MALAT1 knockdown via intraocular injection of… vs Scramble shRNA/siRNA or untreated…
Design
Preclinical, Blinded manner for tube formation assay observation
Follow-up
Up to 5 months after diabetes induction
Authors
Loading...
Hypothesis-generating for MALAT1 inhibition in diabetic retinopathy; prospective human studies required before clinical adoption.
Does MALAT1 knockdown improve retinal microvascular dysfunction in diabetic models?
p-value: p=<0.05
Inhibition of lncRNA-MALAT1 ameliorates diabetes-induced microvascular dysfunction and may serve as a potential target for anti-angiogenic therapy in diabetic retinopathy.
Yao et al. (2014) studied Diabetic retinopathy. MALAT1 knockdown vs. Scramble shRNA/siRNA was evaluated on Retinal microvascular dysfunction (pericyte loss, capillary degeneration, microvascular leakage) (p=<0.05). MALAT1 knockdown significantly ameliorated diabetic retinopathy in vivo by reducing pericyte loss and microvascular leakage, and regulated endothelial cell function via p38 MAPK signaling.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: